- Home
- DTIL vs KPTI Comparison
DTIL vs KPTI Comparison
Compare DTIL & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DTIL
- KPTI
- Stock Information
- Founded
- DTIL 2006
- KPTI 2008
- Country
- DTIL United States
- KPTI United States
- Employees
- DTIL N/A
- KPTI N/A
- Industry
- DTIL Biotechnology: Pharmaceutical Preparations
- KPTI Biotechnology: Pharmaceutical Preparations
- Sector
- DTIL Health Care
- KPTI Health Care
- Exchange
- DTIL Nasdaq
- KPTI Nasdaq
- Market Cap
- DTIL 51.6M
- KPTI 44.5M
- IPO Year
- DTIL 2019
- KPTI 2013
- Fundamental
- Price
- DTIL $4.49
- KPTI $4.21
- Analyst Decision
- DTIL Strong Buy
- KPTI Strong Buy
- Analyst Count
- DTIL 2
- KPTI 7
- Target Price
- DTIL $47.00
- KPTI $45.43
- AVG Volume (30 Days)
- DTIL 549.2K
- KPTI 138.8K
- Earning Date
- DTIL 07-31-2025
- KPTI 08-05-2025
- Dividend Yield
- DTIL N/A
- KPTI N/A
- EPS Growth
- DTIL N/A
- KPTI N/A
- EPS
- DTIL N/A
- KPTI N/A
- Revenue
- DTIL $51,141,000.00
- KPTI $142,126,000.00
- Revenue This Year
- DTIL N/A
- KPTI $2.09
- Revenue Next Year
- DTIL $53.21
- KPTI $12.90
- P/E Ratio
- DTIL N/A
- KPTI N/A
- Revenue Growth
- DTIL N/A
- KPTI 1.19
- 52 Week Low
- DTIL $3.61
- KPTI $3.51
- 52 Week High
- DTIL $11.09
- KPTI $16.95
- Technical
- Relative Strength Index (RSI)
- DTIL 54.93
- KPTI 41.48
- Support Level
- DTIL $4.08
- KPTI $4.23
- Resistance Level
- DTIL $4.38
- KPTI $5.14
- Average True Range (ATR)
- DTIL 0.28
- KPTI 0.38
- MACD
- DTIL 0.05
- KPTI 0.04
- Stochastic Oscillator
- DTIL 85.26
- KPTI 24.45
About DTIL Precision BioSciences Inc.
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.
About KPTI Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.